Makela Ashley V, Schott Melissa A, Sehl Olivia C, Gevaert Julia J, Foster Paula J, Contag Christopher H
Michigan State University, Institute for Quantitative Health Science and Engineering East Lansing MI USA
Western University, Robarts Research Institute, Department of Medical Biophysics London ON Canada.
Nanoscale Adv. 2022 Jul 25;4(17):3617-3623. doi: 10.1039/d2na00008c. eCollection 2022 Aug 23.
The use of imaging to detect and monitor the movement and accumulation of cells in living subjects can provide significant insights that can improve our understanding of metastasis and guide therapeutic development. For cell tracking using Magnetic Resonance Imaging (MRI), cells are labeled with iron oxides and the effects of the iron on water provides contrast. However, due to low specificity and difficulties in quantification with MRI, other modalities and approaches need to be developed. Magnetic Particle Imaging (MPI) is an emerging imaging technique which directly detects iron, allowing for a specific, quantitative and sensitive readout. Here, we use MPI to image iron-labeled tumor cells longitudinally, from implantation and growth at a primary site to movement to distant anatomic sites. bioluminescent imaging (BLI) was used to localize tumor metastases and computed tomography (CT) allowed for correlation of these signals to anatomic locations. These three imaging modalities provide information on immune escape and metastasis of iron-labeled, and unlabeled, tumor cells, and the accumulation of cell-free iron contrast over time. We localized iron signals by MPI and tumor cells BLI, and correlated these positive contrast images with CT scans to reveal the anatomic sites with cancer cells; histologic analysis confirmed the presence of iron-labeled tumor cells in the tissues, suggesting that the metastatic cells retained enough iron for MPI detection. The use of multi-modality cell tracking reveals the movement, accumulation and fates of labeled cells that will be helpful understanding cancer progression and guiding the development of targeted therapies.
Nanoscale Adv. 2022-7-25
Mater Today Phys. 2023-3
Quant Imaging Med Surg. 2025-4-1
ACS Appl Mater Interfaces. 2025-4-9
ACS Appl Mater Interfaces. 2024-6-19
J Magn Reson Imaging. 2025-1
Front Med (Lausanne). 2023-5-31
ACS Appl Nano Mater. 2020-5-22
J Vis Exp. 2019-1-20
Nat Commun. 2018-10-15
Br J Cancer. 2017-11-21